erbitux

Now, Erbitux has been approved after all, and ImClone´s stock has rebounded.

现在，西妥昔单抗毕竟还是获批了，英克隆的股价也已反弹。

The 222 patients treated with Erbitux and chemotherapy survived for an average of 40 weeks.

接受艾比特思和化学疗法联合治疗的222名患者平均幸存了40周。

Erbitux targets a protein known as epidermal growth factor receptor, or EGFR, to block the signal.

Erbitux定向作用于一种蛋白质表皮生长因素受体或EGFR阻断其信号。

Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).

例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。

ImClone will keep 39 per cent of US revenues from Erbitux, with Bristol-Myers Squibb taking the rest.

英克隆将提留西妥昔单抗在美收入的39%，而百时美施贵宝将获得其余部分。